抗肥胖化合物及其作用机理的最新进展：综述

Skinner, A.C.; Ravanbakht, S.N.; Skelton, J.A.; Perrin, E.M.; Armstrong, S.C. Prevalence of obesity and severe obesity in US children, 1999-2016. Pediatrics, 2018, 141(3), e20173459
[http://dx.doi.org/10.1542/peds.2017-3459] [PMID: 29483202]

Hales, C.M.; Carroll, M.D.; Fryar, C.D.; Ogden, C.L. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief, 2017, (288), 1-8.
[PMID: 29155689]

Lobstein, T.; Jackson-Leach, R.; Moodie, M.L.; Hall, K.D.; Gortmaker, S.L.; Swinburn, B.A.; James, W.P.T.; Wang, Y.; McPherson, K. Child and adolescent obesity: part of a bigger picture. Lancet, 2015, 385(9986), 2510-2520.
[http://dx.doi.org/10.1016/S0140-6736(14)61746-3] [PMID: 25703114]

Ng, M.; Fleming, T.; Robinson, M.; Thomson, B.; Graetz, N.; Margono, C.; Mullany, E.C.; Biryukov, S.; Abbafati, C.; Abera, S.F.; Abraham, J.P.; Abu-Rmeileh, N.M.; Achoki, T.; AlBuhairan, F.S.; Alemu, Z.A.; Alfonso, R.; Ali, M.K.; Ali, R.; Guzman, N.A.; Ammar, W.; Anwari, P.; Banerjee, A.; Barquera, S.; Basu, S.; Bennett, D.A.; Bhutta, Z.; Blore, J.; Cabral, N.; Nonato, I.C.; Chang, J.C.; Chowdhury, R.; Courville, K.J.; Criqui, M.H.; Cundiff, D.K.; Dabhadkar, K.C.; Dandona, L.; Davis, A.; Dayama, A.; Dharmaratne, S.D.; Ding, E.L.; Durrani, A.M.; Esteghamati, A.; Farzadfar, F.; Fay, D.F.; Feigin, V.L.; Flaxman, A.; Forouzanfar, M.H.; Goto, A.; Green, M.A.; Gupta, R.; Hafezi-Nejad, N.; Hankey, G.J.; Harewood, H.C.; Havmoeller, R.; Hay, S.; Hernandez, L.; Husseini, A.; Idrisov, B.T.; Ikeda, N.; Islami, F.; Jahangir, E.; Jassal, S.K.; Jee, S.H.; Jeffreys, M.; Jonas, J.B.; Kabagambe, E.K.; Khalifa, S.E.; Kengne, A.P.; Khader, Y.S.; Khang, Y.H.; Kim, D.; Kimokoti, R.W.; Kinge, J.M.; Kokubo, Y.; Kosen, S.; Kwan, G.; Lai, T.; Leinsalu, M.; Li, Y.; Liang, X.; Liu, S.; Logroscino, G.; Lotufo, P.A.; Lu, Y.; Ma, J.; Mainoo, N.K.; Mensah, G.A.; Merriman, T.R.; Mokdad, A.H.; Moschandreas, J.; Naghavi, M.; Naheed, A.; Nand, D.; Narayan, K.M.; Nelson, E.L.; Neuhouser, M.L.; Nisar, M.I.; Ohkubo, T.; Oti, S.O.; Pedroza, A.; Prabhakaran, D.; Roy, N.; Sampson, U.; Seo, H.; Sepanlou, S.G.; Shibuya, K.; Shiri, R.; Shiue, I.; Singh, G.M.; Singh, J.A.; Skirbekk, V.; Stapelberg, N.J.; Sturua, L.; Sykes, B.L.; Tobias, M.; Tran, B.X.; Trasande, L.; Toyoshima, H.; van de Vijver, S.; Vasankari, T.J.; Veerman, J.L.; Velasquez-Melendez, G.; Vlassov, V.V.; Vollset, S.E.; Vos, T.; Wang, C.; Wang, X.; Weiderpass, E.; Werdecker, A.; Wright, J.L.; Yang, Y.C.; Yatsuya, H.; Yoon, J.; Yoon, S.J.; Zhao, Y.; Zhou, M.; Zhu, S.; Lopez, A.D.; Murray, C.J.; Gakidou, E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014, 384(9945), 766-781.
[http://dx.doi.org/10.1016/S0140-6736(14)60460-8] [PMID: 24880830]

Popkin, B.M.; Adair, L.S.; Ng, S.W. Global nutrition transition and the pandemic of obesity in developing countries. Nutr. Rev., 2012, 70(1), 3-21.
[http://dx.doi.org/10.1111/j.1753-4887.2011.00456.x] [PMID: 22221213]

Poobalan, A.; Aucott, L. Obesity among young adults in developing countries: a systematic overview. Curr. Obes. Rep., 2016, 5(1), 2-13.
[http://dx.doi.org/10.1007/s13679-016-0187-x] [PMID: 26883372]

Jia, P.; Xue, H.; Zhang, J.; Wang, Y. Time trend and demographic and geographic disparities in child-hood obesity prevalence in china-evidence from twenty years of longitudinal data. Int. J. Environ. Res. Public Health, 2017, 14(4), 369.
[http://dx.doi.org/10.3390/ijerph14040369] [PMID: 28362361]

Zhang, J.; Wang, H.; Wang, Z.; Du, W.; Su, C.; Zhang, J.; Jiang, H.; Jia, X.; Huang, F.; Ouyang, Y.; Wang, Y.; Zhang, B. Prevalence and stabilizing trends in overweight and obesity among children and adolescents in China, 2011-2015. BMC Public Health, 2018, 18(1), 571.
[http://dx.doi.org/10.1186/s12889-018-5483-9] [PMID: 29716560]

Witkamp, R.F. 3.15-Biologically active compounds in food products and their effects on obesity and diabetes. Comprehensive Natural Products II, 2010, 46(1), 509-545.
[http://dx.doi.org/10.1016/B978-008045382-8.00063-0]

Kumar, R.B.; Aronne, L.J. Review of multimodal therapies for obesity treatment: Including dietary, counseling strategies, and pharmacologic interventions. Tech. Gastrointest. Endosc., 2017, 19(1), 12-17.
[http://dx.doi.org/10.1016/j.tgie.2016.11.003]

Tilg, H.; Hotamisligil, G.S. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology, 2006, 131(3), 934-945.
[http://dx.doi.org/10.1053/j.gastro.2006.05.054] [PMID: 16952562]

Zhang, W.L.; Zhu, L.; Jiang, J.G. Active ingredients from natural botanicals in the treatment of obesity. Obes. Rev., 2014, 15(12), 957-967.
[http://dx.doi.org/10.1111/obr.12228] [PMID: 25417736]

Martel, J.; Ojcius, D.M.; Chang, C-J.; Lin, C-S.; Lu, C-C.; Ko, Y-F.; Tseng, S-F.; Lai, H-C.; Young, J.D. Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat. Rev. Endocrinol., 2017, 13(3), 149-160.
[http://dx.doi.org/10.1038/nrendo.2016.142] [PMID: 27636731]

Yun, J.W. Possible anti-obesity therapeutics from nature--a review. Phytochemistry, 2010, 71(14-15), 1625-1641.
[http://dx.doi.org/10.1016/j.phytochem.2010.07.011] [PMID: 20732701]

Sinha, R. Role of addiction and stress neurobiology on food intake and obesity. Biol. Psychol., 2018, 131, 5-13.
[http://dx.doi.org/10.1016/j.biopsycho.2017.05.001] [PMID: 28479142]

Redman, L.M.; Ravussin, E. Lorcaserin for the treatment of obesity. Drugs Today (Barc), 2010, 46(12), 901-910.
[http://dx.doi.org/10.1358/dot.2010.46.12.1556433] [PMID: 21589947]

Heal, D.J.; Smith, S.L.; Fisas, A.; Codony, X.; Buschmann, H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther., 2008, 117(2), 207-231.
[http://dx.doi.org/10.1016/j.pharmthera.2007.08.006] [PMID: 18068807]

Thomsen, W.J.; Grottick, A.J.; Menzaghi, F.; Reyes-Saldana, H.; Espitia, S.; Yuskin, D.; Whelan, K.; Martin, M.; Morgan, M.; Chen, W.; Al-Shamma, H.; Smith, B.; Chalmers, D.; Behan, D. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J. Pharmacol. Exp. Ther., 2008, 325(2), 577-587.
[http://dx.doi.org/10.1124/jpet.107.133348] [PMID: 18252809]

Smith, S.R.; Weissman, N.J.; Anderson, C.M.; Sanchez, M.; Chuang, E.; Stubbe, S.; Bays, H.; Shanahan, W.R. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med., 2010, 363(3), 245-256.
[http://dx.doi.org/10.1056/NEJMoa0909809] [PMID: 20647200]

Smith, S.R.; Prosser, W.A.; Donahue, D.J.; Morgan, M.E.; Anderson, C.M.; Shanahan, W.R. APD356-004 Study Group. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring), 2009, 17(3), 494-503.
[http://dx.doi.org/10.1038/oby.2008.537] [PMID: 19057523]

Martin, C.K.; Redman, L.M.; Zhang, J.; Sanchez, M.; Anderson, C.M.; Smith, S.R.; Ravussin, E. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J. Clin. Endocrinol. Metab., 2011, 96(3), 837-845.
[http://dx.doi.org/10.1210/jc.2010-1848] [PMID: 21190985]

Yang, H.Y.; Tae, J.; Seo, Y.W.; Kim, Y.J.; Im, H.Y.; Choi, G.D.; Cho, H.; Park, W.K.; Kwon, O.S.; Cho, Y.S.; Ko, M.; Jang, H.; Lee, J.; Choi, K.; Kim, C.H.; Lee, J.; Pae, A.N. Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity. Eur. J. Med. Chem., 2013, 63(5), 558-569.
[http://dx.doi.org/10.1016/j.ejmech.2013.02.020] [PMID: 23537943]

Wren, A.M.; Seal, L.J.; Cohen, M.A.; Brynes, A.E.; Frost, G.S.; Murphy, K.G.; Dhillo, W.S.; Ghatei, M.A.; Bloom, S.R. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab., 2001, 86(12), 5992.
[http://dx.doi.org/10.1210/jcem.86.12.8111] [PMID: 11739476]

Takahashi, B.; Funami, H.; Iwaki, T.; Maruoka, H.; Shibata, M.; Koyama, M.; Nagahira, A.; Kamiide, Y.; Kanki, S.; Igawa, Y.; Muto, T. Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model. Bioorg. Med. Chem., 2015, 23(15), 4792-4803.
[http://dx.doi.org/10.1016/j.bmc.2015.05.047] [PMID: 26100441]

Kroog, G.S.; Jensen, R.T.; Battey, J.F. Mammalian bombesin receptors. Med. Res. Rev., 1995, 15(5), 389-417.
[http://dx.doi.org/10.1002/med.2610150502] [PMID: 8531502]

Guan, X.M.; Chen, H.; Dobbelaar, P.H.; Dong, Y.; Fong, T.M.; Gagen, K.; Gorski, J.; He, S.; Howard, A.D.; Jian, T.; Jiang, M.; Kan, Y.; Kelly, T.M.; Kosinski, J.; Lin, L.S.; Liu, J.; Marsh, D.J.; Metzger, J.M.; Miller, R.; Nargund, R.P.; Palyha, O.; Shearman, L.; Shen, Z.; Stearns, R.; Strack, A.M.; Stribling, S.; Tang, Y.S.; Wang, S.P.; White, A.; Yu, H.; Reitman, M.L. Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab., 2010, 11(2), 101-112.
[http://dx.doi.org/10.1016/j.cmet.2009.12.008] [PMID: 20096642]

Ohki-Hamazaki, H.; Watase, K.; Yamamoto, K.; Ogura, H.; Yamano, M.; Yamada, K.; Maeno, H.; Imaki, J.; Kikuyama, S.; Wada, E.; Wada, K. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity. Nature, 1997, 390(6656), 165-169.
[http://dx.doi.org/10.1038/36568] [PMID: 9367152]

Chobanian, H.R.; Guo, Y.; Liu, P.; Chioda, M.; Lanza, T.J., Jr; Chang, L.; Kelly, T.M.; Kan, Y.; Palyha, O.; Guan, X.M.; Marsh, D.J.; Metzger, J.M.; Gorski, J.N.; Raustad, K.; Wang, S.P.; Strack, A.M.; Miller, R.; Pang, J.; Madeira, M.; Lyons, K.; Dragovic, J.; Reitman, M.L.; Nargund, R.P.; Lin, L.S. Discovery of MK-7725, A potent, selective bombesin receptor subtype-3 agonist for the treatment of obesity. ACS Med. Chem. Lett., 2012, 3(3), 252-256.
[http://dx.doi.org/10.1021/ml200304j] [PMID: 24900461]

Liu, J.; He, S.; Jian, T.; Dobbelaar, P.H.; Sebhat, I.K.; Lin, L.S.; Goodman, A.; Guo, C.; Guzzo, P.R.; Hadden, M.; Henderson, A.J.; Pattamana, K.; Ruenz, M.; Sargent, B.J.; Swenson, B.; Yet, L.; Tamvakopoulos, C.; Peng, Q.; Pan, J.; Kan, Y.; Palyha, O.; Kelly, T.M.; Guan, X.M.; Howard, A.D.; Marsh, D.J.; Metzger, J.M.; Reitman, M.L.; Wyvratt, M.J.; Nargund, R.P. Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity. Bioorg. Med. Chem. Lett., 2010, 20(7), 2074-2077.
[http://dx.doi.org/10.1016/j.bmcl.2010.02.076] [PMID: 20219372]

Kowalski, T.J.; McBriar, M.D. Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin. Investig. Drugs, 2004, 13(9), 1113-1122.
[http://dx.doi.org/10.1517/13543784.13.9.1113] [PMID: 15330743]

Ludwig, D.S.; Tritos, N.A.; Mastaitis, J.W.; Kulkarni, R.; Kokkotou, E.; Elmquist, J.; Lowell, B.; Flier, J.S.; Maratos-Flier, E. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J. Clin. Invest., 2001, 107(3), 379-386.
[http://dx.doi.org/10.1172/JCI10660] [PMID: 11160162]

Mihalic, J.T.; Chen, X.; Fan, P.; Chen, X.; Fu, Y.; Liang, L.; Reed, M.; Tang, L.; Chen, J.L.; Jaen, J.; Li, L.; Dai, K. Discovery of a novel series of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett., 2011, 21(23), 7001-7005.
[http://dx.doi.org/10.1016/j.bmcl.2011.09.110] [PMID: 22019296]

Schober, G.; Arnold, M.; Birtles, S.; Buckett, L.K.; Pacheco-López, G.; Turnbull, A.V.; Langhans, W.; Mansouri, A. Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats. J. Lipid Res., 2013, 54(5), 1369-1384.
[http://dx.doi.org/10.1194/jlr.M035154] [PMID: 23449193]

Qian, Y.; Wertheimer, S.J.; Ahmad, M.; Cheung, A.W-H.; Firooznia, F.; Hamilton, M.M.; Hayden, S.; Li, S.; Marcopulos, N.; McDermott, L.; Tan, J.; Yun, W.; Guo, L.; Pamidimukkala, A.; Chen, Y.; Huang, K.S.; Ramsey, G.B.; Whittard, T.; Conde-Knape, K.; Taub, R.; Rondinone, C.M.; Tilley, J.; Bolin, D. Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes. J. Med. Chem., 2011, 54(7), 2433-2446.
[http://dx.doi.org/10.1021/jm101580m] [PMID: 21413799]

Schober, G.; Arnold, M.; Birtles, S.; Buckett, L.; Turnbull, A.V.; Langhans, W. Diacylglycerol acyl-transferase-1 (DGAT-1) inhibition reduces food intake and blunts postprandial increases in circulating fat metabolites in high fat diet (HFD)-fed rats. Appetite, 2010, 54(3), 674-674.
[http://dx.doi.org/10.1016/j.appet.2010.04.180]

Saely, C.H.; Geiger, K.; Drexel, H. Brown versus white adipose tissue: a mini-review. Gerontology, 2012, 58(1), 15-23.
[http://dx.doi.org/10.1159/000321319] [PMID: 21135534]

Enerbäck, S. Brown adipose tissue in humans. Int. J. Obes., 2010, 34(Suppl. 1), S43-S46.
[http://dx.doi.org/10.1038/ijo.2010.183] [PMID: 20935666]

Fujioka, S.; Matsuzawa, Y.; Tokunaga, K.; Tarui, S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism, 1987, 36(1), 54-59.
[http://dx.doi.org/10.1016/0026-0495(87)90063-1] [PMID: 3796297]

Solini, A.; Bonora, E.; Bonadonna, R.; Castellino, P.; DeFronzo, R.A. Protein metabolism in human obesity: relationship with glucose and lipid metabolism and with visceral adipose tissue. J. Clin. Endocrinol. Metab., 1997, 82(8), 2552-2558.
[http://dx.doi.org/10.1210/jc.82.8.2552] [PMID: 9253333]

Yamamoto, T.; Yamaguchi, H.; Miki, H.; Kitamura, S.; Nakada, Y.; Aicher, T.D.; Pratt, S.A.; Kato, K. A novel coenzyme A:diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity. Eur. J. Pharmacol., 2011, 650(2-3), 663-672.
[http://dx.doi.org/10.1016/j.ejphar.2010.10.040] [PMID: 21034741]

Yamamoto, T.; Yamaguchi, H.; Miki, H.; Shimada, M.; Nakada, Y.; Ogino, M.; Asano, K.; Aoki, K.; Tamura, N.; Masago, M.; Kato, K. Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets. Eur. J. Pharmacol., 2010, 640(1-3), 243-249.
[http://dx.doi.org/10.1016/j.ejphar.2010.04.050] [PMID: 20478303]

Fox, B.M.; Furukawa, N.; Hao, X.; Iio, K.; Inaba, T.; Jackson, S.M.; Kayser, F.; Labelle, M.; Li, K.; Matsui, T. Fused bicyclic nitrogen-containing heterocycles; Google Patents, 2007.

Tsuda, N.; Kumadaki, S.; Higashi, C.; Ozawa, M.; Shinozaki, M.; Kato, Y.; Hoshida, K.; Kikuchi, S.; Nakano, Y.; Ogawa, Y.; Furusako, S. Intestine-targeted DGAT1 inhibition improves obesity and insulin resistance without skin aberrations in mice. PLoS One, 2014, 9(11), e112027-e112027.
[http://dx.doi.org/10.1371/journal.pone.0112027] [PMID: 25405858]

Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688.
[PMID: 10529898]

Girroir, E.E.; Hollingshead, H.E.; He, P.; Zhu, B.; Perdew, G.H.; Peters, J.M. Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. Biochem. Biophys. Res. Commun., 2008, 371(3), 456-461.
[http://dx.doi.org/10.1016/j.bbrc.2008.04.086] [PMID: 18442472]

Braissant, O.; Foufelle, F.; Scotto, C.; Dauça, M.; Wahli, W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology, 1996, 137(1), 354-366.
[http://dx.doi.org/10.1210/endo.137.1.8536636] [PMID: 8536636]

Szkudelska, K.; Szkudelski, T. Resveratrol, obesity and diabetes. Eur. J. Pharmacol., 2010, 635(1-3), 1-8.
[http://dx.doi.org/10.1016/j.ejphar.2010.02.054] [PMID: 20303945]

Szkudelski, T.; Szkudelska, K. Anti-diabetic effects of resveratrol. Ann. N. Y. Acad. Sci., 2011, 1215(1), 34-39.
[http://dx.doi.org/10.1111/j.1749-6632.2010.05844.x] [PMID: 21261639]

Aguirre, L.; Fernández-Quintela, A.; Arias, N.; Portillo, M.P. Resveratrol: anti-obesity mechanisms of action. Molecules, 2014, 19(11), 18632-18655.
[http://dx.doi.org/10.3390/molecules191118632] [PMID: 25405284]

Lasa, A.; Churruca, I.; Eseberri, I.; Andrés-Lacueva, C.; Portillo, M.P. Delipidating effect of resveratrol metabolites in 3T3-L1 adipocytes. Mol. Nutr. Food Res., 2012, 56(10), 1559-1568.
[http://dx.doi.org/10.1002/mnfr.201100772] [PMID: 22945685]

Fernández-Quintela, A.; Carpéné, C.; Fernández, M.; Aguirre, L.; Milton-Laskibar, I.; Contreras, J.; Portillo, M.P. Anti-obesity effects of resveratrol: comparison between animal models and humans. J. Physiol. Biochem., 2016, 73(3), 417-429.
[http://dx.doi.org/10.1007/s13105-016-0544-y] [PMID: 27981508]

Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R.H.; van de Weijer, T.; Goossens, G.H.; Hoeks, J.; van der Krieken, S.; Ryu, D.; Kersten, S.; Moonen-Kornips, E.; Hesselink, M.K.C.; Kunz, I.; Schrauwen-Hinderling, V.B.; Blaak, E.; Auwerx, J.; Schrauwen, P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab., 2011, 14(5), 612-622.
[http://dx.doi.org/10.1016/j.cmet.2011.10.002] [PMID: 22055504]

Ghadieh, H.E.; Smiley, Z.N.; Kopfman, M.W.; Najjar, M.G.; Hake, M.J.; Najjar, S.M. Chlorogenic acid/chromium supplement rescues diet-induced insulin resistance and obesity in mice. Nutr. Metab. (Lond.), 2015, 12(1), 19.
[http://dx.doi.org/10.1186/s12986-015-0014-5] [PMID: 26045713]

Cho, A-S.; Jeon, S-M.; Kim, M-J.; Yeo, J.; Seo, K-I.; Choi, M-S.; Lee, M-K. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem. Toxicol., 2010, 48(3), 937-943.
[http://dx.doi.org/10.1016/j.fct.2010.01.003] [PMID: 20064576]

Diamant, M.; Heine, R.J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs, 2003, 63(13), 1373-1405.
[http://dx.doi.org/10.2165/00003495-200363130-00004] [PMID: 12825962]

Saltiel, A.R.; Olefsky, J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 1996, 45(12), 1661-1669.
[http://dx.doi.org/10.2337/diab.45.12.1661] [PMID: 8922349]

Bhattarai, B.R.; Kafle, B.; Hwang, J-S.; Ham, S.W.; Lee, K-H.; Park, H.; Han, I-O.; Cho, H. Novel thiazolidinedione derivatives with anti-obesity effects: dual action as PTP1B inhibitors and PPAR-γ activators. Bioorg. Med. Chem. Lett., 2010, 20(22), 6758-6763.
[http://dx.doi.org/10.1016/j.bmcl.2010.08.130] [PMID: 20850970]

Tercel, M.; Marnane, R.N.; Tatnell, M.A.; Stevenson, R.J.; Halim, A.; Lu, G.L.; Duchesnes, C.; Truong, M.; Denny, W.A.; Wilson, W.R.; Mountjoy, K.G. An indoline-derived compound that markedly reduces mouse body weight. Int. J. Obes., 2013, 37(5), 685-692.
[http://dx.doi.org/10.1038/ijo.2012.97] [PMID: 22732909]

Shimano, H.; Yahagi, N.; Amemiya-Kudo, M.; Hasty, A.H.; Osuga, J.; Tamura, Y.; Shionoiri, F.; Iizuka, Y.; Ohashi, K.; Harada, K.; Gotoda, T.; Ishibashi, S.; Yamada, N. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem., 1999, 274(50), 35832-35839.
[http://dx.doi.org/10.1074/jbc.274.50.35832] [PMID: 10585467]

Shimano, H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog. Lipid Res., 2001, 40(6), 439-452.
[http://dx.doi.org/10.1016/S0163-7827(01)00010-8] [PMID: 11591434]

Zhao, X.; Xiaoli, ; Zong, H.; Abdulla, A.; Yang, E.S.; Wang, Q.; Ji, J.Y.; Pessin, J.E.; Das, B.C.; Yang, F. Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity. Diabetes, 2014, 63(7), 2464-2473.
[http://dx.doi.org/10.2337/db13-0835] [PMID: 24608444]

Kim, D.D.; Krishnarajah, J.; Lillioja, S.; de Looze, F.; Marjason, J.; Proietto, J.; Shakib, S.; Stuckey, B.G.A.; Vath, J.E.; Hughes, T.E. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes. Metab., 2015, 17(6), 566-572.
[http://dx.doi.org/10.1111/dom.12457] [PMID: 25732625]

Hughes, T.E.; Kim, D.D.; Marjason, J.; Proietto, J.; Whitehead, J.P.; Vath, J.E. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring), 2013, 21(9), 1782-1788.
[http://dx.doi.org/10.1002/oby.20356] [PMID: 23512440]

Rupnick, M.A.; Panigrahy, D.; Zhang, C.Y.; Dallabrida, S.M.; Lowell, B.B.; Langer, R.; Folkman, M.J. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10730-10735.
[http://dx.doi.org/10.1073/pnas.162349799] [PMID: 12149466]

Lee, S.; Yang, W.K.; Song, J.H.; Ra, Y.M.; Jeong, J.H.; Choe, W.; Kang, I.; Kim, S.S.; Ha, J. Anti-obesity effects of 3-hydroxychromone derivative, a novel small-molecule inhibitor of glycogen synthase kinase-3. Biochem. Pharmacol., 2013, 85(7), 965-976.
[http://dx.doi.org/10.1016/j.bcp.2012.12.023] [PMID: 23337568]

Shi, L.; Wang, J.; Wang, Y.; Feng, Y. MDG-1, an Ophiopogon polysaccharide, alleviates hyperlipidemia in mice based on metabolic profile of bile acids. Carbohydr. Polym., 2016, 150, 74-81.
[http://dx.doi.org/10.1016/j.carbpol.2016.05.008] [PMID: 27312615]

Edwards, P.A.; Kast, H.R.; Anisfeld, A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res., 2002, 43(1), 2-12.
[PMID: 11792716]

Calkin, A.C.; Tontonoz, P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat. Rev. Mol. Cell Biol., 2012, 13(4), 213-224.
[http://dx.doi.org/10.1038/nrm3312] [PMID: 22414897]

Souza, G.A.; Ebaid, G.X.; Seiva, F.R.; Rocha, K.H.; Galhardi, C.M.; Mani, F.; Novelli, E.L. N-acetylcysteine an allium plant compound improves high-sucrose diet-induced obesity and related effects. Evid. Based Complement. Alternat. Med., 2011, 2011, 643269
[http://dx.doi.org/10.1093/ecam/nen070] [PMID: 19001480]

Mela, D.J.; Rogers, P.J. Energy intake and expenditure: basic concepts and issues; Springer: US, 1998.

Bonet, M.L.; Oliver, P.; Palou, A. Pharmacological and nutritional agents promoting browning of white adipose tissue. Biochim. Biophys. Acta, 2013, 1831(5), 969-985.
[http://dx.doi.org/10.1016/j.bbalip.2012.12.002] [PMID: 23246573]

Ricquier, D.; Bouillaud, F. Mitochondrial uncoupling proteins: from mitochondria to the regulation of energy balance. J. Physiol., 2000, 529(Pt 1), 3-10.
[http://dx.doi.org/10.1111/j.1469-7793.2000.00003.x] [PMID: 11080246]

Brand, M.D.; Esteves, T.C. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab., 2005, 2(2), 85-93.
[http://dx.doi.org/10.1016/j.cmet.2005.06.002] [PMID: 16098826]

Maeda, H.; Hosokawa, M.; Sashima, T.; Murakami-Funayama, K.; Miyashita, K. Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model. Mol. Med. Rep., 2009, 2(6), 897-902.
[http://dx.doi.org/10.3892/mmr_00000189] [PMID: 21475918]

Gammone, M.A.; D’Orazio, N. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar. Drugs, 2015, 13(4), 2196-2214.
[http://dx.doi.org/10.3390/md13042196] [PMID: 25871295]

Maeda, H. Nutraceutical effects of fucoxanthin for obesity and diabetes therapy: a review. J. Oleo Sci., 2015, 64(2), 125-132.
[http://dx.doi.org/10.5650/jos.ess14226] [PMID: 25748372]

Woo, M.N.; Jeon, S.M.; Shin, Y.C.; Lee, M.K.; Kang, M.A.; Choi, M.S. Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice. Mol. Nutr. Food Res., 2009, 53(12), 1603-1611.
[http://dx.doi.org/10.1002/mnfr.200900079] [PMID: 19842104]

Fu, Y.Y.; Zhang, M.; Turner, N.; Zhang, L.N.; Dong, T.C.; Gu, M.; Leslie, S.J.; Li, J.Y.; Nan, F.J.; Li, J. A novel chemical uncoupler ameliorates obesity and related phenotypes in mice with diet-induced obesity by modulating energy expenditure and food intake. Diabetologia, 2013, 56(10), 2297-2307.
[http://dx.doi.org/10.1007/s00125-013-2987-9] [PMID: 23912111]

Zhang, Z.; Zhang, H.; Li, B.; Meng, X.; Wang, J.; Zhang, Y.; Yao, S.; Ma, Q.; Jin, L.; Yang, J.; Wang, W.; Ning, G. Berberine activates thermogenesis in white and brown adipose tissue. Nat. Commun., 2014, 5(5), 5493.
[http://dx.doi.org/10.1038/ncomms6493] [PMID: 25423280]

Ma, X.; Xu, L.; Alberobello, A.T.; Gavrilova, O.; Bagattin, A.; Skarulis, M.; Liu, J.; Finkel, T.; Mueller, E. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab., 2015, 22(4), 695-708.
[http://dx.doi.org/10.1016/j.cmet.2015.08.005] [PMID: 26344102]

Wankhade, U.D.; Shen, M.; Yadav, H.; Thakali, K.M. Novel browning agents, mechanisms, and therapeutic potentials of brown adipose tissue. BioMed Res. Int., 2016, 2016, 2365609
[http://dx.doi.org/10.1155/2016/2365609] [PMID: 28105413]

Silvester, A.J.; Aseer, K.R.; Yun, J.W. Dietary polyphenols and their roles in fat browning. J. Nutr. Biochem., 2019, 64, 1-12.
[http://dx.doi.org/10.1016/j.jnutbio.2018.09.028] [PMID: 30414469]

Joo, J.I.; Kim, D.H.; Choi, J-W.; Yun, J.W. Proteomic analysis for antiobesity potential of capsaicin on white adipose tissue in rats fed with a high fat diet. J. Proteome Res., 2010, 9(6), 2977-2987.
[http://dx.doi.org/10.1021/pr901175w] [PMID: 20359164]

Choi, J.H.; Kim, S.W.; Yu, R.; Yun, J.W. Monoterpene phenolic compound thymol promotes browning of 3T3-L1 adipocytes. Eur. J. Nutr., 2017, 56(7), 2329-2341.
[http://dx.doi.org/10.1007/s00394-016-1273-2] [PMID: 27431894]

Parray, H.A.; Lone, J.; Park, J.P.; Choi, J.W.; Yun, J.W. Magnolol promotes thermogenesis and attenuates oxidative stress in 3T3-L1 adipocytes. Nutrition, 2018, 50, 82-90.
[http://dx.doi.org/10.1016/j.nut.2018.01.017] [PMID: 29547798]

Gregoire, F.M.; Smas, C.M.; Sul, H.S. Understanding adipocyte differentiation. Physiol. Rev., 1998, 78(3), 783-809.
[http://dx.doi.org/10.1152/physrev.1998.78.3.783] [PMID: 9674695]

Gregoire, F.M. Adipocyte differentiation: from fibroblast to endocrine cell. Exp. Biol. Med. (Maywood), 2001, 226(11), 997-1002.
[http://dx.doi.org/10.1177/153537020122601106]

White, U.A.; Stephens, J.M. Transcriptional factors that promote formation of white adipose tissue. Mol. Cell. Endocrinol., 2010, 318(1-2), 10-14.
[http://dx.doi.org/10.1016/j.mce.2009.08.023] [PMID: 19733624]

Cristancho, A.G.; Lazar, M.A. Forming functional fat: a growing understanding of adipocyte differentiation. Nat. Rev. Mol. Cell Biol., 2011, 12(11), 722-734.
[http://dx.doi.org/10.1038/nrm3198] [PMID: 21952300]

Hwang, J.T.; Lee, M.S.; Kim, H.J.; Sung, M.J.; Kim, H.Y.; Kim, M.S.; Kwon, D.Y. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother. Res., 2009, 23(2), 262-266.
[http://dx.doi.org/10.1002/ptr.2606] [PMID: 18844326]

Hwang, J-T.; Kim, S-H.; Lee, M-S.; Kim, S.H.; Yang, H-J.; Kim, M-J.; Kim, H-S.; Ha, J.; Kim, M.S.; Kwon, D.Y. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem. Biophys. Res. Commun., 2007, 364(4), 1002-1008.
[http://dx.doi.org/10.1016/j.bbrc.2007.10.125] [PMID: 17971295]

Siraj, F.M.; SathishKumar, N.; Kim, Y.J.; Kim, S.Y.; Yang, D.C. Ginsenoside F2 possesses anti-obesity activity via binding with PPARγ and inhibiting adipocyte differentiation in the 3T3-L1 cell line. J. Enzyme Inhib. Med. Chem., 2015, 30(1), 9-14.
[http://dx.doi.org/10.3109/14756366.2013.871006] [PMID: 24666293]

Gu, W.; Kim, K.A.; Kim, D.H. Ginsenoside Rh1 ameliorates high fat diet-induced obesity in mice by inhibiting adipocyte differentiation. Biol. Pharm. Bull., 2013, 36(1), 102-107.
[http://dx.doi.org/10.1248/bpb.b12-00558] [PMID: 23302642]

Park, D.; Yoon, M.; Compound, K. Compound K, a novel ginsenoside metabolite, inhibits adipocyte differentiation in 3T3-L1 cells: involvement of angiogenesis and MMPs. Biochem. Biophys. Res. Commun., 2012, 422(2), 263-267.
[http://dx.doi.org/10.1016/j.bbrc.2012.04.142] [PMID: 22575448]

Liu, Q.; Zhang, X.L.; Tao, R.Y.; Niu, Y.J.; Chen, X.G.; Tian, J.Y.; Ye, F. Rhein, an inhibitor of adipocyte differentiation and adipogenesis. J. Asian Nat. Prod. Res., 2011, 13(8), 714-723.
[http://dx.doi.org/10.1080/10286020.2011.586341] [PMID: 21751839]

Seo, J.B.; Choe, S.S.; Jeong, H.W.; Park, S.W.; Shin, H.J.; Choi, S.M.; Park, J.Y.; Choi, E.W.; Kim, J.B.; Seen, D.S.; Jeong, J.Y.; Lee, T.G. Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism. Exp. Mol. Med., 2011, 43(4), 205-215.
[http://dx.doi.org/10.3858/emm.2011.43.4.025] [PMID: 21389766]

Seo, J.B.; Park, S.W.; Choe, S.S.; Jeong, H.W.; Park, J.Y.; Choi, E.W.; Seen, D.S.; Jeong, J.Y.; Lee, T.G. Foenumoside B from Lysimachia foenum-graecum inhibits adipocyte differentiation and obesity induced by high-fat diet. Biochem. Biophys. Res. Commun., 2012, 417(2), 800-806.
[http://dx.doi.org/10.1016/j.bbrc.2011.12.039] [PMID: 22197824]

Rahman, N.; Jeon, M.; Song, H.Y.; Kim, Y.S. Cryptotanshinone, a compound of Salvia miltiorrhiza inhibits pre-adipocytes differentiation by regulation of adipogenesis-related genes expression via STAT3 signaling. Phytomedicine, 2016, 23(1), 58-67.
[http://dx.doi.org/10.1016/j.phymed.2015.12.004] [PMID: 26902408]

Altaf, Q.A.; Barnett, A.H.; Tahrani, A.A. Novel therapeutics for type 2 diabetes: insulin resistance. Diabetes Obes. Metab., 2015, 17(4), 319-334.
[http://dx.doi.org/10.1111/dom.12400] [PMID: 25308775]

de Luca, C.; Olefsky, J.M. Inflammation and insulin resistance. FEBS Lett., 2008, 582(1), 97-105.
[http://dx.doi.org/10.1016/j.febslet.2007.11.057] [PMID: 18053812]

Kajimoto, Y.; Kaneto, H. Role of oxidative stress in pancreatic beta-cell dysfunction. Ann. N. Y. Acad. Sci., 2004, 1011(1), 168-176.
[http://dx.doi.org/10.1196/annals.1293.017] [PMID: 15126294]

Matsuzawa-Nagata, N.; Takamura, T.; Ando, H.; Nakamura, S.; Kurita, S.; Misu, H.; Ota, T.; Yokoyama, M.; Honda, M.; Miyamoto, K.; Kaneko, S. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism, 2008, 57(8), 1071-1077.
[http://dx.doi.org/10.1016/j.metabol.2008.03.010] [PMID: 18640384]

Ravussin, E.; Smith, S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann. N. Y. Acad. Sci., 2002, 967(1), 363-378.
[http://dx.doi.org/10.1111/j.1749-6632.2002.tb04292.x] [PMID: 12079864]

Dandona, P.; Aljada, A.; Bandyopadhyay, A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol., 2004, 25(1), 4-7.
[http://dx.doi.org/10.1016/j.it.2003.10.013] [PMID: 14698276]

Ye, J. Mechanisms of insulin resistance in obesity. Front. Med., 2013, 7(1), 14-24.
[http://dx.doi.org/10.1007/s11684-013-0262-6] [PMID: 23471659]

Ding, L.; Li, J.; Song, B.; Xiao, X.; Zhang, B.; Qi, M.; Huang, W.; Yang, L.; Wang, Z. Curcumin rescues high fat diet-induced obesity and insulin sensitivity in mice through regulating SREBP pathway. Toxicol. Appl. Pharmacol., 2016, 304, 99-109.
[http://dx.doi.org/10.1016/j.taap.2016.05.011] [PMID: 27208389]

Shao, W.; Yu, Z.; Chiang, Y.; Yang, Y.; Chai, T.; Foltz, W.; Lu, H.; Fantus, I.G.; Jin, T. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One, 2012, 7(1), e28784
[http://dx.doi.org/10.1371/journal.pone.0028784] [PMID: 22253696]

Zheng, Z.G.; Zhou, Y.P.; Zhang, X.; Thu, P.M.; Xie, Z.S.; Lu, C.; Pang, T.; Xue, B.; Xu, D.Q.; Chen, Y.; Chen, X.W.; Li, H.J.; Xu, X. Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation. Biochem. Pharmacol., 2016, 122, 42-61.
[http://dx.doi.org/10.1016/j.bcp.2016.10.016] [PMID: 27816546]

Fjære, E.; Aune, U.L.; Røen, K.; Keenan, A.H.; Ma, T.; Borkowski, K.; Kristensen, D.M.; Novotny, G.W.; Mandrup-Poulsen, T.; Hudson, B.D.; Milligan, G.; Xi, Y.; Newman, J.W.; Haj, F.G.; Liaset, B.; Kristiansen, K.; Madsen, L. Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. J. Biol. Chem., 2014, 289(23), 16032-16045.
[http://dx.doi.org/10.1074/jbc.M113.525220] [PMID: 24742673]

Ozcan, L.; Xu, X.; Deng, S.X.; Ghorpade, D.S.; Thomas, T.; Cremers, S.; Hubbard, B.; Serrano-Wu, M.H.; Gaestel, M.; Landry, D.W.; Tabas, I. Treatment of obese insulin-resistant mice with an allosteric MAPKAPK2/3 inhibitor lowers blood glucose and improves insulin sensitivity. Diabetes, 2015, 64(10), 3396-3405.
[http://dx.doi.org/10.2337/db14-1945] [PMID: 26068544]

Xu, N.; Zhang, L.; Dong, J.; Zhang, X.; Chen, Y.G.; Bao, B.; Liu, J. Low-dose diet supplement of a natural flavonoid, luteolin, ameliorates diet-induced obesity and insulin resistance in mice. Mol. Nutr. Food Res., 2014, 58(6), 1258-1268.
[http://dx.doi.org/10.1002/mnfr.201300830] [PMID: 24668788]

Zhang, L.; Han, Y.J.; Zhang, X.; Wang, X.; Bao, B.; Qu, W.; Liu, J. Luteolin reduces obesity-associated insulin resistance in mice by activating AMPKα1 signalling in adipose tissue macrophages. Diabetologia, 2016, 59(10), 2219-2228.
[http://dx.doi.org/10.1007/s00125-016-4039-8] [PMID: 27377644]

Luft, V.C.; Schmidt, M.I.; Pankow, J.S.; Couper, D.; Ballantyne, C.M.; Young, J.H.; Duncan, B.B. Chronic inflammation role in the obesity-diabetes association: a case-cohort study. Diabetol. Metab. Syndr., 2013, 5(1), 31.
[http://dx.doi.org/10.1186/1758-5996-5-31] [PMID: 23806173]

Monteiro, R.; Azevedo, I. Chronic inflammation in obesity and the metabolic syndrome Chronic in-flammation in obesity and the metabolic syndrome. Mediators Inflamm., 2010, 2010, pii: 289645
[http://dx.doi.org/10.1155/2010/289645] [PMID: 20706689]

González-Chávez, A.; Elizondo-Argueta, S.; Gutiérrez-Reyes, G.; León-Pedroza, J.I. Pathophysiological implications between chronic inflammation and the development of diabetes and obesity. Cir. Cir., 2011, 79(2), 209-216.
[PMID: 21631985]

Dixon, R.A.; Ferreira, D. Genistein. Phytochemistry, 2002, 60(3), 205-211.
[http://dx.doi.org/10.1016/S0031-9422(02)00116-4] [PMID: 12031439]

Ibrahim, A.S.; El-Shishtawy, M.M.; Peña, A., Jr; Liou, G.I. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol. Vis., 2010, 16, 2033-2042.
[PMID: 21042558]

Saisho, Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocr. Metab. Immune Disord. Drug Targets, 2015, 15(3), 196-205.
[http://dx.doi.org/10.2174/1871530315666150316124019] [PMID: 25772174]

Evia-Viscarra, M.L.; Rodea-Montero, E.R.; Apolinar-Jiménez, E.; Muñoz-Noriega, N.; García-Morales, L.M.; Leaños-Pérez, C.; Figueroa-Barrón, M.; Sánchez-Fierros, D.; Reyes-García, J.G. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J. Pediatr. Endocrinol. Metab., 2012, 25(1-2), 41-49.
[http://dx.doi.org/10.1515/jpem-2011-0469] [PMID: 22570949]

Fidan, E.; Onder Ersoz, H.; Yilmaz, M.; Yilmaz, H.; Kocak, M.; Karahan, C.; Erem, C. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol., 2011, 48(4), 297-302.
[http://dx.doi.org/10.1007/s00592-011-0276-y] [PMID: 21424914]

Lu, A.; Wu, H. Structural mechanisms of inflammasome assembly. FEBS J., 2015, 282(3), 435-444.
[http://dx.doi.org/10.1111/febs.13133] [PMID: 25354325]

Honda, H.; Nagai, Y.; Matsunaga, T.; Okamoto, N.; Watanabe, Y.; Tsuneyama, K.; Hayashi, H.; Fujii, I.; Ikutani, M.; Hirai, Y.; Muraguchi, A.; Takatsu, K. Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation. J. Leukoc. Biol., 2014, 96(6), 1087-1100.
[http://dx.doi.org/10.1189/jlb.3A0114-005RR] [PMID: 25210146]

Oh, D.Y.; Walenta, E.; Akiyama, T.E.; Lagakos, W.S.; Lackey, D.; Pessentheiner, A.R.; Sasik, R.; Hah, N.; Chi, T.J.; Cox, J.M.; Powels, M.A.; Di Salvo, J.; Sinz, C.; Watkins, S.M.; Armando, A.M.; Chung, H.; Evans, R.M.; Quehenberger, O.; McNelis, J.; Bogner-Strauss, J.G.; Olefsky, J.M.A.A. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat. Med., 2014, 20(8), 942-947.
[http://dx.doi.org/10.1038/nm.3614] [PMID: 24997608]

Lederberg, J. Infectious history. Science, 2000, 288(5464), 287-293.
[http://dx.doi.org/10.1126/science.288.5464.287] [PMID: 10777411]

Lin, C.S.; Chang, C.J.; Lu, C.C.; Martel, J.; Ojcius, D.M.; Ko, Y.F.; Young, J.D.; Lai, H.C. Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. Biomed. J., 2014, 37(5), 259-268.
[http://dx.doi.org/10.4103/2319-4170.138314] [PMID: 25179725]

DiBaise, J.K.; Zhang, H.; Crowell, M.D.; Krajmalnik-Brown, R.; Decker, G.A.; Rittmann, B.E. Gut microbiota and its possible relationship with obesity. Mayo Clin. Proc., 2008, 83(4), 460-469.
[http://dx.doi.org/10.4065/83.4.460] [PMID: 18380992]

Shen, J.; Obin, M.S.; Zhao, L. The gut microbiota, obesity and insulin resistance. Mol. Aspects Med., 2013, 34(1), 39-58.
[http://dx.doi.org/10.1016/j.mam.2012.11.001] [PMID: 23159341]

Murphy, E.F.; Cotter, P.D.; Healy, S.; Marques, T.M.; O’Sullivan, O.; Fouhy, F.; Clarke, S.F.; O’Toole, P.W.; Quigley, E.M.; Stanton, C.; Ross, P.R.; O’Doherty, R.M.; Shanahan, F. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut, 2010, 59(12), 1635-1642.
[http://dx.doi.org/10.1136/gut.2010.215665] [PMID: 20926643]

de La Serre, C.B.; Ellis, C.L.; Lee, J.; Hartman, A.L.; Rutledge, J.C.; Raybould, H.E. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 299(2), G440-G448.
[http://dx.doi.org/10.1152/ajpgi.00098.2010] [PMID: 20508158]

Verdam, F.J.; Fuentes, S.; de Jonge, C.; Zoetendal, E.G.; Erbil, R.; Greve, J.W.; Buurman, W.A.; de Vos, W.M.; Rensen, S.S. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring), 2013, 21(12), E607-E615.
[http://dx.doi.org/10.1002/oby.20466] [PMID: 23526699]

Kootte, R.S.; Vrieze, A.; Holleman, F.; Dallinga-Thie, G.M.; Zoetendal, E.G.; de Vos, W.M.; Groen, A.K.; Hoekstra, J.B.L.; Stroes, E.S.; Nieuwdorp, M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes. Metab., 2012, 14(2), 112-120.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01483.x] [PMID: 21812894]

Hu, Y.; Davies, G.E. Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia, 2010, 81(5), 358-366.
[http://dx.doi.org/10.1016/j.fitote.2009.10.010] [PMID: 19861153]

Zhang, X.; Zhao, Y.; Zhang, M.; Pang, X.; Xu, J.; Kang, C.; Li, M.; Zhang, C.; Zhang, Z.; Zhang, Y.; Li, X.; Ning, G.; Zhao, L. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One, 2012, 7(8), e42529
[http://dx.doi.org/10.1371/journal.pone.0042529] [PMID: 22880019]

Xie, W.; Gu, D.; Li, J.; Cui, K.; Zhang, Y. Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. PLoS One, 2011, 6(9), e24520
[http://dx.doi.org/10.1371/journal.pone.0024520] [PMID: 21915347]

Masumoto, S.; Terao, A.; Yamamoto, Y.; Mukai, T.; Miura, T.; Shoji, T. Non-absorbable apple procyanidins prevent obesity associated with gut microbial and metabolomic changes. Sci. Rep., 2016, 6, 31208.
[http://dx.doi.org/10.1038/srep31208] [PMID: 27506289]

Witkamp, R.F. Biologically active compounds in food products and their effects on obesity and diabetes. Comp. Nat. Prod., 2010, 3, 509-545.
[http://dx.doi.org/10.1016/B978-008045382-8.00063-0]